ARISER: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC—Results and implications for adjuvant clinical trials.
暂无分享,去创建一个
A. Belldegrun | A. Pantuck | S. Störkel | K. Chamie | O. Wilhelm | P. Bevan | P. Kloepfer | B. Fall | S. Störkel